Michael Gutch - 16 Jul 2021 Form 4 Insider Report for Entasis Therapeutics Holdings Inc.

Reporting relationship: Chief Financial Officer and Chief Business Officer
Issuer ticker: N/A
Reported as of: 16 Jul 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Feb 2022, 15:05:08 UTC
Prior SEC filing: 28 Jun 2021
Next SEC filing: 20 Oct 2021
Source filing: View source filing
Reporting owner signature: Elizabeth M. Keiley as Attorney-in-Fact for Michael Gutch

Key filing fact

Michael Gutch filed Form 4 for Entasis Therapeutics Holdings Inc. on 15 Feb 2022.

Key facts

This page summarizes Michael Gutch's Form 4 filing for Entasis Therapeutics Holdings Inc..
6 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 15 Feb 2022, 15:05.

Change

Previous filing in this sequence was filed on 28 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ETTX transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -30,006
Change %: -100%
Price
Shares after: 0
Date: 16 Jul 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,006
Exercise price: $6.85
Footnotes: F1, F2

ETTX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +23,081
Change %
Price
Shares after: 23,081
Date: 16 Jul 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,081
Exercise price: $2.44
Footnotes: F3

ETTX transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -15,956
Change %: -100%
Price
Shares after: 0
Date: 16 Jul 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,956
Exercise price: $15.00
Footnotes: F4, F5

ETTX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +8,863
Change %
Price
Shares after: 8,863
Date: 16 Jul 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,863
Exercise price: $2.44
Footnotes: F5, F6

ETTX transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -56,500
Change %: -100%
Price
Shares after: 0
Date: 16 Jul 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 56,500
Exercise price: $5.66
Footnotes: F7, F8

ETTX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +43,460
Change %
Price
Shares after: 43,460
Date: 16 Jul 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 43,460
Exercise price: $2.44
Footnotes: F8, F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option will vest on December 6, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the last day of the month, subject to Reporting Person continuing to provide service through each such date.

Footnote F2

On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,006 shares of issuer's common stock granted to the Reporting Person on May 1, 2018. In exchange, the Reporting Person received a replacement option for 23,081 shares of issuer's common stock, having an exercise price of $2.44 per share.

Footnote F3

The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date.

Footnote F4

The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option shall vest on September 25, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Footnote F5

On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,956 shares of issuer's common stock granted to the Reporting Person on September 25, 2018. In exchange, the Reporting Person received a replacement option for 8,863 shares of issuer's common stock, having an exercise price of $2.44 per share.

Footnote F6

Ninety-four (94%) of this award will vest on July 16, 2022, and one-third of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date.

Footnote F7

The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option shall vest on January 1, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Footnote F8

On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 56,500 shares of issuer's common stock granted to the Reporting Person on January 18, 2019. In exchange, the Reporting Person received a replacement option for 43,460 shares of issuer's common stock, having an exercise price of $2.44 per share.

Footnote F9

Eighty-five (85%) of this award will vest on July 16, 2022, and one-seventh of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date.

SEC remarks

Chief Financial Officer and Chief Business Officer